Diagnostics

 

 

Diagnostics play a key role in curbing resistance and improving appropriate use of antimicrobials. Hear from diagnostic developers and heads of microbiology on innovative rapid diagnostics and antimicrobial susceptibly tests. Also featured are the presentations from hospitals and pharmacists on the uptake and use of new diagnostics within the hospital setting.

 

Diagnostics, Thursday 7 November 2019

Conference Registration

Concrete Commercial Initiatives

Jonathan Van-Tam
08:40

Keynote address: UK’s efforts to combat resistance and create a sustainable commercial environment for existing and future antibiotics

09:20

Sponsored keynote address

TITLE SPONSOR SLOT
10:20

SPEED NETWORKING FOLLOWED BY NETWORKING COFFEE BREAK

Development

Ribhi Shawar
Diagnostics
11:15

Diagnostic devices for antimicrobial susceptibility and resistance - FDA update on recent initiatives and advancements

Ephraim Tsalik
Diagnostics
11:55

Host-based diagnostics for discriminating bacterial and viral infection – diagnostic performance in patients in international and resource-limited environments

Kfir Oved
Diagnostics
12:15

Unlocking the host response’s power to differentiate bacterial from viral infection

12:35

Networking Lunch Break

ROUNDTABLES (1-hour roundtable sessions split between 2 rounds of 30min)

Christine Årdal
14:10

Roundtable 10 Market Access - overcoming access barriers for smaller markets - considerations for countries and developers

Christian Lillis
14:10

Roundtable 11 Patient Advocacy - what can the growing antibiotic patient advocacy community do to generate public awareness and support for AMR initiativ

Marco Taglietti
14:10

Roundtable 12 Candida auris - a ticking time bomb: responding to an urgent global public health threat

Dave Ousterout
14:10

Roundtable 13 Phage development - Opportunities in development of novel phage therapies

Debbie Goff
14:10

Roundtable 14 Global collaboration – global stakeholder collaboration between clinicians, policy makers, pharmaceutical/diagnostic companies is needed to succeed at ASP

Amy Kirby
14:10

Roundtable 15 Water Quality – understanding transmission of waterborne pathogens and how the international community can combat the spread of resistance through integrating advanced lab techniques

Jeffrey Cies
14:10

Roundtable 16 Drug dosing – anti-infective underdosing and opportunities for customized drug dosing

Kartik Cherabuddi
14:10

Roundtable 2 Controlling c.dif - determining who to test and how to prevent additional outbreaks in the hospital

Richard Vickers
14:10

Roundtable 3 Innovation & stewardship - Advancing narrow spectrum, new mechanism antibiotics as precision agents to by-pass resistance and to support antibiotic stewardship.

Advancing narrow spectrum, new mechanism antibiotics as precision agents to by-pass resistance and to support antibiotic stewardship. Developing the right antibiotic to treat the right patient and improve clinical outcomes.
Justine Ross
14:10

Roundtable 4 Customizing Epic – the use of Epic Stewardship Navigator to aid antimicrobial stewardship, pharmacist workflow, and prescribing habits in a tertiary cancer center

Colm Leonard
14:10

Roundtable 5 Antimicrobial value assessment - a look into the role of HTA in the UK's testing of novel assessment and delinked payment program

Jay K Varma
14:10

Roundtable 6 Policy in Africa- advancing advocacy, political commitment, resistance data collection and Africa-wide stewardship guidelines for antimicrobial use in humans

Brian Tse
14:10

Roundtable 7 Non-traditional antibacterials – advancing non-traditional product types from discovery phase to clinical development

Ryan Devies
14:10

Roundtable 8 Advancing Preclinical – working with regulators through pre-clinical to advance distinct classes of small molecule drugs

Jane Knisely
14:10

Roundtable 9 Supporting development - NIH programs filling the gaps in traditional and non-traditional therapeutic discovery & development with grants, contracts, in-vitro and in vivo screening

NIH programs filling the gaps in traditional and non-traditionaltherapeutic discovery & development with grants, contracts,in-vitro and in vivo screening and manufacturing capabilities and more.

Diagnostics in the Hospital

Eric Wenzler
Diagnostics
15:15

A-Z of hospital and pharmacy use of new and existing rapid diagnostics –diagnosing multi drug resistant organisms

Laia Fernandez
Diagnostics
15:35

A major biofilm issue: early detection of Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis

Cecile Balding
16:35

Networking coffee break

Supported by BD

18:15

Drinks Reception

Thomas Cueni
18:15

Welcoming remarks by AMR Industry Alliance

Cocktail Reception hosted by AMR Industry Alliance
last published: 11/Oct/19 22:05

Diagnostics, Friday 8 November 2019

08:00

Conference Registration

Tom Lowery
09:25

Keynote Address: The impact of rapid, direct-from-blood diagnostics in enabling changes in clinical decisions and improving outcomes

10:30

Networking coffee break

Industry Collaboration

Mary Motyl
Diagnostics
11:15

Reversing the “pitch” between diagnostics providers and industry

Benefits and feasibility of pharma communicating their needs diagnostic developers first to accelerate development of badly needed tests.
Ian Critchley
Diagnostics
11:35

Diagnostic engagement through antibiotic clinical development & commercialization – increasing collaboration to tackle AMR

Ian Critchley
Diagnostics
11:35

Diagnostic engagement through antibiotic clinical development & commercialization – increasing collaboration to tackle AMR

Speaker to be announced.
Diagnostics
11:55

GOLD SPONSOR SESSION

If you are interested in sponsoring this session in the Diagnostics Track, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com.

12:35

Networking Lunch Break

13:40

Networking Lunch Break Resumes

ROUNDTABLES (1-hour roundtable sessions split between 2 rounds of 30min)

Clifford Mcdonald
14:10

Roundtable 10 Microbiome & CDC – Discussing a vision for precision public health novel approaches to treating infection prevention through the microbiome

Minh-Hong Nguyen
14:10

Roundtable 11 Developing diagnostics – novel approaches to development

Minh-Hong Nguyen, Director, Transplant Infectious Diseases, Director, Antimicrobial Management Program, University of Pittsburgh
Courtney Jones
14:10

Roundtable 12 Infection intervention – using the microbiome to make antibiotics effective again

Mary Millard
14:10

Roundtable 13 Patient practitioner education – how hospitals can and should educate patients on infection risks and easy to implement prevention practices

Wes Kim
14:10

Roundtable 14 SPARK Platform: Pew Charitable Trusts’ Collaborative Discovery Tool for Gram-Negative Antibiotics

Jomana Musmar
14:10

Roundtable 15 One Health - The Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) recommending federal One Health action to address AMR

Sarah De Clercq
14:10

Roundtable 16 AMR in Belgium – Creating a one health National Action Plan on AMR – rollout and next steps

Sumathi Nambiar
14:10

Roundtable 17 FDA Roundtable discussion

Nick Van Hise
14:10

Roundtable 2 The fecal microbiome - new approaches to the treatment of C. difficile infection

Eugean Jiwanmall
14:10

Roundtable 3 Evaluating Diagnostics – Criteria for potential coverage and related decisions - paths for generating, formalizing, & analysing evidence to build & reach consensus

Thomas Heymann
14:10

Roundtable 4 AMR and Sepsis - we are all in this together

Eili Klein
14:10

Roundtable 5 Surveillance

Examining novel metrics for measurement, societal and socioeconomic factors effecting resistance, and how resistance surveillance tools can help educate policymakers on AMR.
Angella Browne
14:10

Roundtable 7 Infection prevention – next wave of infection prevention of multidrug resistant infections through screening, protocol and more

Jeanette Mucha
14:10

Roundtable 8 CARB-X Accelerator – Company perspective on CARB-X Accelerator - What worked and what can be improved?

Abigail Colson
14:10

Roundtable 9 Health Technology Assessment – when it comes to AMR, will HTA be part of the solution or part of the problem?

Wes Kim
14:10

Roundtable: SPARK Platform: Pew Charitable Trusts’ Collaborative Discovery Tool for Gram-Negative Antibiotics

Economics and Value

Robert Sambursky
Diagnostics
15:15

FebriDx: A POC test that simultaneously detects MxA and CRP during presumed acute respiratory infection to improve clinical workflow, reduce unnecessary antibiotics, and save costs

Herman Goossens
Diagnostics
15:35

VALUE-DX: generating evidence on the medical, economic, and public health value of diagnostics in tackling AMR

Herman Goossens, Project Leader, Value-Dx, Director Of Research, Laboratory Of Medical Microbiology, University Of Antwerp
Cassandra Kelly
Diagnostics
15:55

Thinking creatively about diagnostic development – breaking from constraints of conventional development and delivery models

More information available soon
last published: 11/Oct/19 22:05

 

 


GET INVOLVED AT

WORLD ANTI-MICROBIAL RESISTANCE CONGRESS

 

To Sponsor Or Exhibit

 


André Singer
andre.singer@terrapinn.com
+1 646.619.1797

 

 

Press & Media Partnerships

 


Shannon McGorry
shannon.mcgorry@terrapinn.com
+1 646.619.1840

 

 

To Speak

 


Claire Murphy
claire.murphy@terrapinn.com
+1 646.619.1784

 

Sign Up for Event Updates